| 臺大學術典藏 |
2020-03-05T06:28:40Z |
Oxaliplatin-based chemotherapy is more beneficial in KRAS mutant than in KRAS wild-type metastatic colorectal cancer patients
|
Cheng A.-L.; Chang Y.-L.; Yeh K.-H.; Tseng L.-H.; Lin L.-I.; Hung J.-S.; Lin B.-R.; Liang J.-T.; Lin Y.-.; Liang Y.-H.; Tsai J.-H.; JAU-YU LIAU |
| 臺大學術典藏 |
2018-09-10T14:58:15Z |
Oxaliplatin-based chemotherapy is more beneficial in KRAS mutant than in KRAS wild-type metastatic colorectal cancer patients
|
ANN-LII CHENG; Chang, Yih-Leong; Chang, Yih-Leong; Yeh, Kun-Huei; Yeh, Kun-Huei; Cheng, Ann-Lii; Cheng, Ann-Lii; Lin, Yu-Lin;Liang, Yi-Hsin;Tsai, Jia-Huei;Liau, Jau-Yu;Liang, Jin-Tung;Lin, Been-Ren;Hung, Ji-Shiang;Lin, Liang-In;Tseng, Li-Hui;Chang, Yih-Leong;Yeh, Kun-Huei;Cheng, Ann-Lii; Lin, Yu-Lin;Liang, Yi-Hsin;Tsai, Jia-Huei;Liau, Jau-Yu;Liang, Jin-Tung;Lin, Been-Ren;Hung, Ji-Shiang;Lin, Liang-In;Tseng, Li-Hui;Chang, Yih-Leong;Yeh, Kun-Huei;Cheng, Ann-Lii; Lin, Yu-Lin;Liang, Yi-Hsin;Tsai, Jia-Huei;Liau, Jau-Yu;Liang, Jin-Tung;Lin, Been-Ren;Hung, Ji-Shiang;Lin, Liang-In;Tseng, Li-Hui;Chang, Yih-Leong;Yeh, Kun-Huei;Cheng, Ann-Lii; LI-HUI TSENG; Lin, Yu-Lin; Liang, Yi-Hsin; Liang, Yi-Hsin; YIH-LEONG CHANG; Jin-Tung Liang; Chang, Jui-Hsing; Tsai, Jia-Huei; Liau, Jau-Yu; BEEN-REN LIN; JAU-YU LIAU; Liang, Jin-Tung; Lin, Been-Ren; LIANG-IN LIN; Lin, Been-Ren; Hung, Ji-Shiang; KUN-HUEI YEH; Ji-Shiang Hung; Lin, Liang-In; Tseng, Li-Hui; 梁逸歆;林亮音;曾麗慧;張逸良;林育麟;鄭安理;葉坤輝;蔡佳惠;洪基翔;林本仁;廖肇裕;梁金銅; 梁逸歆;林亮音;曾麗慧;張逸良;林育麟;鄭安理;葉坤輝;蔡佳惠;洪基翔;林本仁;廖肇裕;梁金銅 |
| 臺大學術典藏 |
2020-03-06T05:26:15Z |
Oxaliplatin-based chemotherapy is more beneficial in KRAS mutant than in KRAS wild-type metastatic colorectal cancer patients
|
Lin Y.-.; Liang Y.-H.; Tsai J.-H.; Liau J.-Y.; Liang J.-T.; Lin B.-R.; Hung J.-S.; Lin L.-I.; Tseng L.-H.; YIH-LEONG CHANG; Yeh K.-H.; Cheng A.-L. |
| 臺大學術典藏 |
2020-03-07T06:56:25Z |
Oxaliplatin-based chemotherapy is more beneficial in KRAS mutant than in KRAS wild-type metastatic colorectal cancer patients
|
YIH-LEONG CHANG; Yeh K.-H.; Cheng A.-L.; Tseng L.-H.; Lin L.-I.; Hung J.-S.; Lin B.-R.; Liau J.-Y.; Liang J.-T.; Tsai J.-H.; Liang Y.-H.; Lin Y.-.; Lin Y.-.;Liang Y.-H.;Tsai J.-H.;Liau J.-Y.;Liang J.-T.;Lin B.-R.;Hung J.-S.;Lin L.-I.;Tseng L.-H.;Yih-Leong Chang;Yeh K.-H.;Cheng A.-L. |
| 臺大學術典藏 |
2020-03-05T07:31:48Z |
Oxaliplatin-based chemotherapy is more beneficial in KRAS mutant than in KRAS wild-type metastatic colorectal cancer patients
|
Lin Y.-.;Liang Y.-H.;Jia-Huei Tsai;Liau J.-Y.;Liang J.-T.;Lin B.-R.;Hung J.-S.;Lin L.-I.;Tseng L.-H.;Chang Y.-L.;Yeh K.-H.;Cheng A.-L.; Lin Y.-.; Liang Y.-H.; JIA-HUEI TSAI; Liau J.-Y.; Liang J.-T.; Lin B.-R.; Hung J.-S.; Lin L.-I.; Tseng L.-H.; Chang Y.-L.; Yeh K.-H.; Cheng A.-L. |
| 臺大學術典藏 |
2021-05-03T02:20:57Z |
Oxaliplatin-based chemotherapy is more beneficial in KRAS mutant than in KRAS wild-type metastatic colorectal cancer patients
|
Lin Y.-.; Liang Y.-H.; Tsai J.-H.; Liau J.-Y.; JIN-TUNG LIANG; Lin B.-R.; Hung J.-S.; Lin L.-I.; Tseng L.-H.; Chang Y.-L.; Yeh K.-H.; Cheng A.-L. |
| 臺大學術典藏 |
2021-08-31T06:42:23Z |
Oxaliplatin-based chemotherapy is more beneficial in KRAS mutant than in KRAS wild-type metastatic colorectal cancer patients
|
Lin Y.-.; Liang Y.-H.; Tsai J.-H.; Liau J.-Y.; Liang J.-T.; Lin B.-R.; Hung J.-S.; Lin L.-I.; Tseng L.-H.; Chang Y.-L.; Yeh K.-H.; ANN-LII CHENG |
| 臺大學術典藏 |
2021-05-07T02:46:38Z |
Oxaliplatin-based chemotherapy is more beneficial in KRAS mutant than in KRAS wild-type metastatic colorectal cancer patients
|
Lin Y.-.; YI-HSIN LIANG; Tsai J.-H.; Liau J.-Y.; Liang J.-T.; Lin B.-R.; Hung J.-S.; Lin L.-I.; Tseng L.-H.; Chang Y.-L.; Yeh K.-H.; Cheng A.-L. |
| 臺大學術典藏 |
2020-03-05T06:28:43Z |
Oxaliplatin-based chemotherapy might provide longer progression-free survival in KRAS mutant metastatic colorectal cancer
|
Cheng A.-L.; Yeh K.-H.; Chang Y.-L.; Hung J.-S.; Lin Y.-L.; JAU-YU LIAU; Yu S.-C.; Tseng L.-H.; Lin L.-I.; Liang J.-T.; Lin B.-R. |
| 國立臺灣大學 |
2013 |
Oxaliplatin-based Chemotherapy Might Provide Longer Progression-Free Survival in KRAS Mutant Metastatic Colorectal Cancer
|
Lin, Yu-Lin; Liau, Jau-Yu; Yu, Shan-Chi; Tseng, Li-Hui; Lin, Liang-In; Liang, Jin-Tung; Lin, Ben-Ren; Hung, Ji-Shiang; Chang, Yih-Leong; Yeh, Kun-Huei; Cheng, Ann-Lii; 林亮音; 曾麗慧; 張逸良; 林育麟; 鄭安理; 葉坤輝; 尤善琦; 洪基翔; 林本仁; 廖肇裕; 梁金銅 |
| 臺大學術典藏 |
2018-09-10T09:48:26Z |
Oxaliplatin-based chemotherapy might provide longer progression-free survival in KRAS mutant metastatic colorectal cancer
|
Lin, Yu-Lin;Liau, Jau-Yu;Yu, Shan-Chi;Tseng, Li-Hui;Lin, Liang-In;Liang, Jin-Tung;Lin, Ben-Ren;Hung, Ji-Shiang;Chang, Yih-Leong;Yeh, Kun-Huei;Cheng, Ann-Lii; Lin, Y.-L. and Liau, J.-Y. and Yu, S.-C. and Tseng, L.-H. and Lin, L.-I. and Liang, J.-T. and Lin, B.-R. and Hung, J.-S. and Chang, Y.-L. and Yeh, K.-H. and Cheng, A.-L.; 林亮音;曾麗慧;張逸良;林育麟;鄭安理;葉坤輝;尤善琦;洪基翔;林本仁;廖肇裕;梁金銅; Lin, Yu-Lin; LI-HUI TSENG; Wang, Yu-Jen; YIH-LEONG CHANG; Huang, Chao-Yuan; Liau, Jau-Yu; Jin-Tung Liang; Hou, Wei-Hsien; Yu, Shan-Chi; Tseng, Li-Hui; JAU-YU LIAU; Wang, Chia-Chun; Lin, Liang-In; Lan, Keng-Hsueh; LIANG-IN LIN; Liang, Jin-Tung; Yu, Hong-Jen; KUN-HUEI YEH; Ji-Shiang Hung; Lin, Ben-Ren; Lai, Ming-Kuen; Hung, Ji-Shiang; YU-LIN LIN; Liu, Shihh-Ping; Pu, Yeong-Shau; Chang, Yih-Leong; ANN-LII CHENG; Cheng, Jason Chia-Hsien; Yeh, Kun-Huei; Cheng, Ann-Lii; 蒲永孝; 余宏政; 成佳憲; 王嘉檇; 賴明坤; 黃昭淵; 劉詩彬; 藍耿學 |
| 臺大學術典藏 |
2020-02-25T05:15:28Z |
Oxaliplatin-based chemotherapy might provide longer progression-free survival in KRAS mutant metastatic colorectal cancer
|
Lin Y.-L.; Liau J.-Y.; Yu S.-C.; Tseng L.-H.; Lin L.-I.; Liang J.-T.; Lin B.-R.; JI-SHIANG HUNG; Chang Y.-L.; Yeh K.-H.; Cheng A.-L. |
| 臺大學術典藏 |
2020-03-05T12:22:25Z |
Oxaliplatin-based chemotherapy might provide longer progression-free survival in KRAS mutant metastatic colorectal cancer
|
Lin Y.-L.; Liau J.-Y.; SHAN-CHI YU; Tseng L.-H.; Lin L.-I.; Liang J.-T.; Lin B.-R.; Hung J.-S.; Chang Y.-L.; Yeh K.-H.; Cheng A.-L. |
| 臺大學術典藏 |
2020-03-06T05:26:20Z |
Oxaliplatin-based chemotherapy might provide longer progression-free survival in KRAS mutant metastatic colorectal cancer
|
Lin Y.-L.; Liau J.-Y.; Yu S.-C.; Tseng L.-H.; Lin L.-I.; Liang J.-T.; Lin B.-R.; Hung J.-S.; YIH-LEONG CHANG; Yeh K.-H.; Cheng A.-L. |
| 臺大學術典藏 |
2020-03-07T06:56:33Z |
Oxaliplatin-based chemotherapy might provide longer progression-free survival in KRAS mutant metastatic colorectal cancer
|
YIH-LEONG CHANG; Yeh K.-H.; Cheng A.-L.; Lin Y.-L.; Liau J.-Y.; Yu S.-C.; Tseng L.-H.; Lin L.-I.; Liang J.-T.; Lin B.-R.; Hung J.-S. |
| 臺大學術典藏 |
2021-01-28T01:06:38Z |
Oxaliplatin-based chemotherapy might provide longer progression-free survival in KRAS mutant metastatic colorectal cancer
|
Lin Y.-L.;Liau J.-Y.;Yu S.-C.;Tseng L.-H.;Lin L.-I.;Liang J.-T.;Lin B.-R.;Hung J.-S.;Chang Y.-L.;Kun-Huei Yeh;Cheng A.-L.; Lin Y.-L.; Liau J.-Y.; Yu S.-C.; Tseng L.-H.; Lin L.-I.; Liang J.-T.; Lin B.-R.; Hung J.-S.; Chang Y.-L.; KUN-HUEI YEH; Cheng A.-L. |
| 臺大學術典藏 |
2021-05-03T02:21:01Z |
Oxaliplatin-based chemotherapy might provide longer progression-free survival in KRAS mutant metastatic colorectal cancer
|
Lin Y.-L.; Liau J.-Y.; Yu S.-C.; Tseng L.-H.; Lin L.-I.; JIN-TUNG LIANG; Lin B.-R.; Hung J.-S.; Chang Y.-L.; Yeh K.-H.; Cheng A.-L. |
| 臺大學術典藏 |
2021-09-01T01:53:54Z |
Oxaliplatin-based chemotherapy might provide longer progression-free survival in KRAS mutant metastatic colorectal cancer
|
Lin Y.-L.; Liau J.-Y.; Yu S.-C.; Tseng L.-H.; Lin L.-I.; Liang J.-T.; Lin B.-R.; Hung J.-S.; Chang Y.-L.; Yeh K.-H.; ANN-LII CHENG |
| 臺大學術典藏 |
2022-03-10T07:58:45Z |
Oxaliplatin-based chemotherapy might provide longer progression-free survival in KRAS mutant metastatic colorectal cancer
|
Lin Y.-L.; Liau J.-Y.; Yu S.-C.; LI-HUI TSENG; Lin L.-I.; Liang J.-T.; Lin B.-R.; Hung J.-S.; Chang Y.-L.; Yeh K.-H.; Cheng A.-L. |
| 臺大學術典藏 |
2022-04-20T06:09:19Z |
Oxaliplatin-based Chemotherapy Might Provide Longer Progression-Free Survival in KRAS Mutant Metastatic Colorectal Cancer
|
Lin, Yu-Lin; Liau, Jau-Yu; SHAN-CHI YU; Tseng, Li-Hui; Lin, Liang-In; Liang, Jin-Tung; BEEN-REN LIN; Hung, Ji-Shiang; Chang, Yih-Leong; Yeh, Kun-Huei; Cheng, Ann-Lii |
| 慈濟大學 |
2009 |
Oxaliplatin-induced gamma-H2AX activation via both p53-dependent and -independent pathways but is not associated with cell cycle arrest in human colorectal cancer cells
|
Chiu, Shu-Jun;Lee, Yi-Jang;Hsu, Tzu-Sheng;Chen, Wen-Shu |
| 中國醫藥大學 |
2009-01 |
Oxaliplatin-induced long QT syndrome in a patient with appendiceal adenocarcinoma
|
羅偉忠(Lo Woei Chung); 廖裕民(Yu-Min Liao)*; 謝清昀(Ching-Yun Hsieh); 林振源(Chen-Yuan Lin) |
| 中國醫藥大學 |
2014-03-16 |
Oxaliplatin-resistance in colorectal cancer cells is mediated by NF-κB/ABCG2 signaling pathway.
|
(Yi-Jiun lin);郭薇雯(Wei-Wen Kuo);黃志揚(Chih-Yang Huang)* |
| 亞洲大學 |
2013.11 |
Oxaliplatin-resistant colorectal cancer cells was mediated by ABCG2/PERK and EGFR/PI3K/Akt/IKK/NF-κB signaling pathway.
|
郭薇雯;黃志揚;HUANG, CHIH-YANG |
| 中國醫藥大學 |
2013-11-02 |
Oxaliplatin-resistant colorectal cancer cells was mediated by ABCG2/PERK and EGFR/PI3K/Akt/IKK/NF-κB signaling pathway.
|
(Yi-Jiun lin);郭薇雯(Wei-Wen Kuo);黃志揚(Chih-Yang Huang)*;黃志揚(Chih-Yang Huang) |
